Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Search
136 result(s) found, displaying 1 to 25
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesProduct warnings across the GLP-1 RA class of medicines have been aligned to ensure consistent information regarding the potential risk of suicidal thoughts or behaviours.
-
Safety updatesOur investigation into the potential for reduced effectiveness of oral contraception during initiation or dose escalations with Mounjaro (tirzepatide) has found that this association could not be ruled out.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesThe Product Information for denosumab products indicated for the treatment of osteoporosis have been updated to strengthen the existing warning for multiple vertebral fractures following discontinuation or delay of treatment.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesNew warnings on hepatotoxicity risk and monitoring recommendations have been added to the Product Information for Veoza (fezolinetant).
-
Safety updatesWe have received 2 serious adverse event cases in neonates in which EMLA (topical prilocaine/lidocaine cream) was applied for a circumcision procedure. Both cases were likely to have involved overdose.
-
Safety updatesResults of our investigation into the safety and efficacy of Vyvanse.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesInformation about the indications for the individual products and how to avoid administration errors.
-
Safety updatesNew warnings added of risks during anaesthesia or deep sedation.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesRisk of Guillain-Barre syndrome added to Product Information.
-
Safety updatesUpdated illustrations clarify how to use measuring syringe for oral solutions.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesUpdates further highlight potential risks of mood-related changes and sexual disorders.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesMore prominent warnings are being added to the Product Information (PI) and Consumer Medicine Information (CMI) for all oral and injectable (systemic) fluoroquinolones to strengthen existing warnings about serious side effects
-
Safety updatesThere may be an increased risk of neurodevelopmental disorders in children born to men who have taken sodium valproate in the 3 months before conception.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.